Introduction
MicroRNAs (miRNAs) are non-coding, single-stranded small RNAs and constitute a novel class of gene regulators that are found in both plants and animals (1) . Mature miRNAs, ranging from 18 to 25 nucleotides in length, processed by two-step cleavage involving Drosha and Dicer are thought to negatively regulate messenger RNA (mRNA).
The mature miRNA binds to target mRNA and induces its cleavage or translational repression depending on the degree of complementarity (2) . Although hundreds of miRNAs have been already cloned, only a small number of them have been characterized.
Recently, several miRNAs have been reported to be involved in cell proliferation or apoptosis in various types of cancers (3, 4) . miR-15a and miR-16 induce apoptosis by targeting BCL2, and these miRNAs are frequently deleted or under-expressed in chronic lymphocytic leukemia (5) . let-7 expression is reduced in lung cancer with poor prognosis (6) and inversely correlates with expression of RAS protein, suggesting a possible mechanism for cancer cell proliferation (7) . Compared to these under-expressed miRNAs, miR-21 has an anti-apoptotic function and is over-expressed in glioblastoma.
Knockdown of miR-21 in glioblastoma cells induced caspase activation, resulting in apoptotic cell death (8) . Thus, miRNAs can act as both tumor suppressor and oncogene.
The miR-17-92 cluster, composed of seven miRNAs (miR-17-5p, miR-17-3p, miR-18a, miR-19a, miR-20a, miR-19b and miR-92-1) and located in intron 3 of the C13orf25 gene, is over-expressed in lung cancer and B-cell lymphoma (9, 10) . Enforced expression of truncated cluster comprising miR-17-5p~19b (miR- 17-19b) , the vertebrate-specific portion of the miR-17-92 cluster, accelerated tumor development in mouse B-cell lymphoma model, suggesting oncogenic function of miR- 17-19b . On the other hand, O'Donnell et al. have reported that expression of oncogenic E2F1 is negatively regulated by miR-17-5p and miR-20a, members of the cluster, implying that they act as a tumor suppressor (11) . Thus, the function of the cluster is still controversial.
In thyroid cancer, over-expression of several miRNAs has been reported. He et al. have reported that three miRNAs (miR-221, miR-222 and miR-146) are over-expressed in papillary thyroid carcinomas (PTCs) and regulate KIT expression (12) . Another group has also shown that miR-221, miR-222 and miR-181b are over-expressed in PTCs, and inhibition of miR-221 by antisense oligonucleotides led to attenuation of cell growth (13) .
In follicular thyroid cancers (FTCs), miR-197 and miR-346 are significantly over-expressed (14) . In vitro over-expression of either miRNA induced cell proliferation, whereas inhibition led to growth arrest. Very recently, Visone et al. have reported that significant decrease in miR-30d, miR-125b, miR-26a and miR-30a-5p was detected in human anaplastic thyroid cancers (ATCs) (15) .
ATCs are highly aggressive and fatal tumors with less than eight months of mean survival after diagnosis (16) . Various treatment patterns including radiation and chemotherapy have been tried in ATCs, but they are mostly unsuccessful (17) . Therefore, the identification of miRNAs involved in proliferation or apoptosis in ATC cells has important therapeutic implications and may lead to establishment of a novel therapy for ATCs. In the present study, we show that mir-17-92 cluster, which is over-expressed in ARO and FRO cells, has a crucial role in cell growth and survival. These findings suggest that the mir-17-92 cluster might be a novel target for ATC treatment.
Materials and Methods

Cell culture.
We used ATC cell lines ARO, FRO (18) and KTC-2 (derived from anaplastic transformed PTC) (19) ; PTC cell lines NPA and TPC-1 (20) ; FTC cell line WRO (21) ; and PT. All cells used in this study are of human origin. ARO, FRO, NPA and WRO were kindly provided by Dr. G. Juillard (University of California, Los Angels, CA, USA). TPC-1 and KTC-2 were kindly provided by Dr. Sato (Cancer Institute, Kanazawa University, Kanazawa, Japan) and Dr. Kurebayashi (Kawasaki Medical School, Kurashiki, Japan), respectively. All cells (except PT) were maintained in RPMI-1640 medium supplemented with 5% fetal bovine serum (FBS) and penicillin/streptomycin at 37ºC in a humidified atmosphere with 5% CO 2 . PT were isolated from thyroid tissues obtained during subtotal thyroidectomy in patients with
Graves' disease and cultured as described previously (22) . All experiments were performed after obtaining hospital ethical committee approval. Informed consent was obtained from each individual.
miRNA microarray.
Small RNAs (~200 nt) were extracted from ARO cells and PT using a mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA). Five micrograms of the small RNAs were subjected to Custom microRNA Array Analysis Service (http://www.hssnet.co.jp/e/2/2_4_5_1.html) (Hokkaido System Science, Sapporo, Japan). The array contained 313 oligonucleotide probes for mature miRNA.
Northern blot analysis. Total RNA was extracted from cells using ISOGEN reagent (Nippon Gene, Tokyo, Japan). Ten micrograms of total RNA were separated on 15%
denaturing polyacrylamide gel and electrotransferred onto Nylon Membrane Positively After equilibration with detection buffer (0.1 M Tris-HCl pH 9.5/0.1 M NaCl), the membrane was incubated with chemiluminescent substrate CDP Star (Roche Diagnostics). Detection was performed using a LAS3000 imaging system (FUJIFILM, Tokyo, Japan). After detection, the membrane was stripped and used for re-hybridization a few times.
Real-time reverse transcription (RT) -polymerase chain reaction (PCR).
The quantitative real-time RT-PCR for miRNA was performed using TaqMan MicroRNA Assay System (Applied Biosystems, Foster City, CA, USA). Briefly, 10 ng of total RNA was reverse transcribed using looped RT primer which is specific for each miRNA. The following amplification was performed using a corresponding TaqMan MicroRNA Assay Mix (Applied Biosystems) in a Thermal Cycler Dice Real-time System (Takara Bio Inc., Ohtsu, Japan). The cycle threshold value, which was determined using second derivative, was used to calculate the normalized expression of the indicated miRNAs using Q-Gene software (23) . Senescence-associated β-galactosidase (SA-β-gal) staining. Cells were fixed with 2% formaldehyde/0.2% glutalaldehyde and assayed for SA-β-gal activity using X-gal (5-bromo-4-chloro-3-indolyl β-D-galactosidase) at pH 6.0 as described previously (24, 25) .
RNA isolation
SA-β-gal-positive cells were detected by bright-field microscopy. The percentages of One system (Nacalai Tesque, Kyoto, Japan). The image was obtained using a LAS3000
imaging system (FUJIFILM).
DNA agarose gel electrophoresis.
Genomic DNA was extracted from the pellets used for protein extraction. The pellets were incubated with 500 µl TEN buffer containing 40 mM Tris-HCl (pH 8.0), 1 mM EDTA, 150 mM NaCl and proteinase K at 55ºC overnight. Then, DNA was extracted using phenol/chloroform/isoamylalcohol method and ethanol precipitation. Four hundred ng of DNA was electrophoretically separated on 1.5% agarose gel. Ethidium bromide was used for staining and the image was obtained using a UV transilluminator.
Statistical analysis. Differences between groups were examined for statistical significance using one-way analysis of variance (ANOVA) followed by Fisher's PLSD.
P value not exceeding 0.05 was considered statistically significant.
Results
Distinct miRNA expression pattern in ATC cells.
To identify miRNAs specifically deregulated in ATC cells, we performed a comprehensive analysis of miRNA expression in ARO cells and PT using miRNA microarrays. Seven percent of miRNAs were over-expressed (> 2.0-fold) and 7% were under-expressed (< 0.5-fold) in ARO cells compared to PT. Fold changes of representative miRNAs expression are listed in Table   1 . All members of miR-17-92 cluster except miR-17-3p were over-expressed in ARO cells. With respect to cancer-related miRNAs, miR-16 was over-expressed, and let-7
and miR-21 were expressed at almost normal level.
Over-expression of miRNAs in miR-17-92 cluster in thyroid cancer cell lines.
Next, we performed Northern blotting to confirm the microarray data and also to check the expressions of several miRNAs in various thyroid cancer cell lines. All members of the miR-17-92 cluster (miR-17-5p, miR-17-3p, miR-18a, miR-19a, miR-20a, miR-19b
and miR-92-1) were robustly over-expressed in ATC cell lines, ARO and FRO (Fig. 1A) .
We also examined some other cancer-related miRNAs. As shown in Fig. 1B , let-7 and miR-21 were expressed at normal to slightly lower level. In ARO cells, the results of Northern blotting were mostly consistent with the microarray data.
miR-106a and miR-106b have high homologous sequence to miR-17-5p (please see Fig.   3C ), raising the possibility that signals detected with the miR-17-5p probe on Northern blot were caused by cross-hybridization to miR-106a and miR-106b. We thus utilized
TaqMan real-time RT-PCR assay that is basically capable of discriminating single mismatched nucleotide (26) . As shown in Fig. 1C , not only miR-17-5p but also miR-106a
and miR-106b were over-expressed in ARO cells. We also observed over-expression of miR-17-3p which has no homologous miRNA, leading to the conclusion that the miR-17-92 cluster was bona fide over-expressed in ARO cells (Fig. 1C) .
Over-expression of miR-17-3p and miR-17-5p in human ATC samples.
We next analyzed expression levels of miR-17-3p and miR-17-5p in clinical human ATC samples and paired adjacent normal tissue. TaqMan real-time RT-PCR assay was also used in this experiment. In 3 of 6 cases, those miRNAs were robustly over-expressed in ATC lesions compared to normal portions (Fig. 2) . Two cases showed decreased expression in ATC lesions, and one case showed no change. This result suggests that the miR-17-92 cluster is over-expressed in some types of ATCs and may have a role in ATC pathogenesis.
miR inhibitors abolish endogenous miRNA expressions.
The miR-17-92 cluster has been reported to be over-expressed in certain types of cancers; however, the function of each individual miRNA in the cluster is still controversial. Since miR-17-19b is vertebrate-specific portion of the miR-17-92 cluster and has been reported to sufficiently act as an oncogene in mouse B cell lymphoma model (9) , we focused in greater detail on miRNAs in miR- 17-19b . To explore biological significance of the members of miR-17-19b, ARO cells were transfected with corresponding miR inhibitor for the each member. Transfection efficiency was initially assessed using FITC-conjugated DNA oligonucleotides and fluorescence microscope, and it was almost 100% in our hands (data not shown). Since miRNA can bind to target mRNA with imperfect match, we used cells treated with transfection reagent only as a control instead of using scrambled oligonucleotides to avoid any unpredictable effects. We then checked specificity of each miR inhibitor by Northern blotting. As shown in Fig. 3A , target miRNAs became undetectable up to 48 hr after transfection and the effect was sequence-specific. However, at 72 hr after transfection, the target miRNA expression was slightly restored (data not shown). In addition, miR-20a, which has a similar sequence to miR-17-5p (2-base difference, Fig. 3C ), and miR-19b, similar to miR-19a
(1-base difference, Fig. 3C ), were also undetectable in cells transfected with LNA-17-5p and LNA-19a, respectively (Fig. 3B) . Moreover, expression of miR-106a and miR-106b, which also have a homologous sequence to miR-17-5p (2-base and 3-base difference, respectively, Fig. 3C ), were similarly affected by LNA-17-5p (Fig.   3B ). Considering that probes for miR-106a and miR-106b probably detect all of miR-17-5p, miR-20a, miR-106a and miR-106b, LNA-17-5p seemed to block all of those miRNAs. On the other hand, the expression of miR-18a, which also shares some homology with miR-17-5p (6-base difference, Fig. 3C ), was not altered by LNA-17-5p (Fig. 3A) . Similarly, miR-20a expression was not affected with LNA-18a (4-base difference, Fig. 3B and 3C ).
Effects of inhibition of endogenous miRNA on ARO and FRO cell growth. We next investigated the effect of inhibition of the members of miR-17-19b on ARO and FRO cell growth. As shown in Fig. 4A and 4B, LNA-17-3p totally suppressed the cell growth, and many detached cells were also observed (data not shown). LNA-17-5p and LNA-19a also dramatically inhibited the growth ( Fig. 4A and 4B ). In contrast to LNA-17-3p, detached cells were barely detected with these miR inhibitors (data not shown). On the other hand, the growth reduction by LNA-18a was moderate, and LNA-21 did not affect at all (Fig. 4A and 4B) . In ARO cells, LNA-17-5p, LNA-17-3p, LNA-18a and LNA-19a suppressed the growth in a dose-dependent fashion, and the inhibitory effect by LNA-17-3p at lower concentration (e.g. 10 pmol/well) was far greater than that of any other miR inhibitors (Fig. 4C) .
LNA-17-3p induces apoptosis.
Since cell detachments were exclusively observed in cells transfected with LNA-17-3p, we next explored the mechanism of growth inhibition by each miR inhibitor. We first investigated caspase activation using D2R substrate after transfection with miR inhibitors. D2R is a cell-permeable nonfluorescent derivative of rhodamine 110. Upon enzymatic cleavage by caspases, this substrate is converted into fluorescent rhodamine 110, enabling us to measure the caspase activity in living cells. Cells were simultaneously stained with DRAQ-5 to evaluate nuclear morphology. As shown in Fig. 5A , intense activation of caspases was found only in the cells transfected with LNA-17-3p. Nuclear apoptotic changes, such as fragmentation or chromatin condensation, were also observed (Fig. 5A, arrowheads) . Despite the significant growth reduction by LNA-17-5p or LNA-19a (Fig. 4) , there was no caspase activation in cells with those inhibitors (Fig. 5A) . We then performed Western blotting to check the activation of caspase 3 and 9, key mediators of apoptosis. As shown in Fig.   5B , both caspases were most clearly activated by LNA-17-3p. LNA-17-3p also caused cleavage of PARP (Fig.5B ) and DNA fragmentation (Fig. 5C ), supporting the evidence of apoptosis induced by LNA-17-3p.
LNA-17-5p induces cell senescence.
We then examined SA-β-gal activity in ARO cells transfected with miR inhibitors. Senescent and/or terminally differentiated cells are known to show enlarged granular phenotype and to possess SA-β-gal activity at pH 6.0 (24) . As shown in Fig. 6A and 6B, the number of SA-β-gal-positive and enlarged cells (miR-19b), respectively (27) . As shown in Fig. 7 , the expression of RB1 and PTEN was clearly increased in cells transfected with LNA-17-5p and LNA-19a, respectively.
Discussion
The miR-17-92 cluster located on the C13orf25 gene has been reported to act as an oncogene in cooperation with MYC in B-cell lymphoma (9) . On the other hand,
O'Donnell et al. have reported that MYC directly binds to the cluster locus and
regulates the transcription of miR-17-92 pri-miRNA. miR-17-5p and miR-20a, members of the miR-17-92 cluster, negatively regulate the expression of E2F1 which promotes cell cycle progression. This finding suggests that these miRNAs have a tumor suppressor activity (11) . These two studies seem to contradict each other. However, E2F1 is reported to induce apoptosis when the level of this protein is excessive (28) . Since MYC also directly induces E2F1 transcription, this mechanism may be present to achieve efficient cell proliferation by tightly regulating the E2F1 expression. Thus, the overall consequence of over-expressing miR-17-92 cluster probably depends on cellular environment and level of target mRNA expression.
In the present work, we have shown the clear over-expression of miRNAs in the miR-17-92 cluster in ATC cell lines and some of the clinical ATC cases. We have also revealed their growth-promoting effects using miR inhibitors. Contrary to our findings, Visone et al. have recently reported that no miR was over-expressed in 10 human ATC samples using microarray technique (15) . This discrepancy could be due to their method of analysis in which mean of fold change was calculated and cutoff of two-fold was applied. In addition, it is generally observed that differences in expression level measured by microarray are usually smaller (underestimated) than actual differences.
Our results suggest that at least in some of ATC cases the miR-17-92 cluster play a role.
However, mechanism of regulating the cluster in each case remains to be explored.
Inhibition of miR-17-3p caused apoptosis with caspase activation. Interestingly, the massive caspase activation was not observed in cells transfected with any other miR inhibitors. miR-17-3p clearly has a distinct function from other members of the cluster.
To our knowledge, however, there is no report regarding target mRNA of miR-17-3p.
Further studies are required to clarify the function of miR-17-3p in ATCs.
Although LNA-17-5p and LNA-19a induced relatively strong growth reduction, only LNA-17-5p caused some degree of cellular senescence in ARO cells. Lazzerini Denchi et al. have proposed the model in which sustained E2F activity induces cellular senescence, whereas temporal E2F activation evokes cell proliferation (29) . Because MYC is over-expressed in ARO cells compared to PT (30) , inhibition of miR-17-5p and miR-20a by LNA-17-5p might cause prolonged E2F1 activation which results in cellular senescence. However, further investigation is required to clarify the detailed mechanism.
One of predicted targets for miR-19a and miR-19b is tumor suppressor PTEN (31) . As expected, definite up-regulation of PTEN was observed in ARO cells transfected with LNA-19a, suggesting that one of targets of miR-19a and miR-19b is PTEN. Germline mutations of PTEN are found in patients with Cowden syndrome, which predisposes to breast and thyroid neoplasia. Recent evidences suggest that reduced expression of PTEN plays a crucial role in thyroid cancer (32) (33) (34) (35) . Moreover, Frisk et al. have reported that PTEN inactivation is involved in highly malignant or late-stage thyroid cancer, especially anaplastic subtype (36) . Our results suggest that over-expression of miR-19a
and miR-19b might be associated with translational suppression of PTEN and induce cell growth in ATCs.
We also found over-expression of miR-106a and miR-106b, and LNA-17-5p inhibited the expression of these homologous miRNAs. Since one of predicted target of these miRNAs is also E2F1 (31) , suppression of them might result in cellular senescence by the above-mentioned mechanism. Moreover, we demonstrated that tumor suppressor RB1 was markedly up-regulated by LNA-17-5p. This is consistent with the report suggesting a post-transcriptional regulation of RB1 by miR-106a over-expression in colon cancer (37) . Therefore, up-regulation of RB1 by LNA-17-5p might result in a negative action in ATC proliferation. Hayashita et al. have reported that the miR-17-92 cluster was over-expressed in the most aggressive form of lung cancer, small-cell cancer and might play a role in its development (10) . Very recently, Matsubara et al. have also demonstrated that inhibition of miR-17-5p and miR-20a caused apoptosis in lung cancer cells, whereas miR-18a and miR-19a did not show significant change in cell growth (38) . The function of each miRNA in the cluster seems to be dependent on type of cells. In ATC cells, downregulation of PTEN might be more important for cell growth as mentioned above.
In PTCs, two groups have concordantly reported that miR-221 and miR-222 are over-expressed and modulate KIT expression (12, 13) . However, in our microarray data, the expression of those miRNAs in ARO cells was conversely under-expressed. ARO cells harbor BRAF V600E mutation and are accordingly thought to originate from PTC (39) , suggesting that those miRNAs may play a role in PTC carcinogenesis but are no longer critical after anaplastic transformation.
In conclusion, our results demonstrate that the miR-17-92 cluster plays an important role in cell growth in some ATCs, and miR inhibitors containing LNA efficiently block cell proliferation and even induce cell death. The miR inhibitors against miR-17-92
cluster could be a novel therapeutic approach to certain types of ATCs. N o r e a g e n t R e a g e n t o n l y R e a g e n t o n l y L N A -1 7 -5 p L N A -1 9 a Figure 7 
